Adhera Therapeutics EBIT

The latest EBIT for ATRX is $-940K as of September 2023. That compares with $-740K in the prior-year period — down 26.9% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside Adhera Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ATRX's EBIT moved from $-740K to $-940K — a 26.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adhera Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, ATRX currently prints $-940K for EBIT, while the sector average sits near $130B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Adhera Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-940K for ATRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting ATRX's EBIT ($-940K), review year-over-year change from $-740K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.